Type 2 Diabetes – Unmet Need – Detailed, Expanded Analysis (US/EU)

The oral type 2 diabetes (T2D) drug market is expected to grow, fueled by rising prevalence and an increasing aging population. Owing to the risk of proteinuria, cardiovascular (CV) complications, and kidney disease associated with T2D, a great unmet need exists for affordable oral drugs that can safely and effectively manage this disease over the long term. The sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as AstraZeneca’s Farxiga / Forxiga and Novo Nordisk’s Rybelsus (an oral glucagon-like peptide-1 [GLP-1] receptor agonist), provide CV and renal benefits, along with weight loss. However, the physical and financial impacts of T2D continue to increase, highlighting the need for more-effective and more-tolerable drug treatments.

QUESTIONS ANSWERED

  • How do endocrinologists rate current T2D oral drug classes, such as the DPP-IV inhibitors, SGLT-2 inhibitors, and meglitinides?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How satisfied are endocrinologists with the performance of Rybelsus, the only oral GLP-1 receptor agonist, in terms of the studied attributes?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European physicians for a hypothetical new T2D drug?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 33 European endocrinologists fielded in March 2021.

Key companies: Novo Nordisk, Merck, AstraZeneca, Boehringer Ingelheim, Eli Lilly

Key drugs: DPP-IV inhibitors, oral GLP-1 receptor agonist, meglitinides, SGLT-2 inhibitors

Table of contents

  • Type 2 Diabetes - Unmet Need - Detailed, Expanded Analysis (US/EU)
    • Executive Summary
      • Unmet Need - Type 2 Diabetes (oral medication) - Executive Summary - April 2021
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Type 2 Diabetes and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Endocrinologists' Prescribing Decisions in Type 2 Diabetes
        • Importance of Efficacy Attributes to Prescribing Decisions in Type 2 Diabetes: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Type 2 Diabetes: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Type 2 Diabetes: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in Type 2 Diabetes: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Type 2 Diabetes: United States
        • Overall Performance of Key Therapies for Type 2 Diabetes: Europe
        • Mean Overall Performance of Key Therapies for Type 2 Diabetes: United States and Europe
        • Relative Performance of Key Therapies for Type 2 Diabetes Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Type 2 Diabetes Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Type 2 Diabetes Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Type 2 Diabetes Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Type 2 Diabetes Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Type 2 Diabetes Across Select Convenience of Administration Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Type 2 Diabetes
        • Surveyed Endocrinologistsu2019 Satisfaction with the Performance of Key Therapies for Type 2 Diabetes on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Endocrinologistsu2019 Satisfaction with the Performance of Key Therapies for Type 2 Diabetes on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Type 2 Diabetes: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Type 2 Diabetes: Europe
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Type 2 Diabetes: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Type 2 Diabetes: Europe
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Type 2 Diabetes: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Type 2 Diabetes: Europe
        • Key Findings: Unmet Need in Type 2 Diabetes and Related Indications
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need in Type 2 Diabetes and Related Indications: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need in Type 2 Diabetes and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Type 2 Diabetes Market and Emerging Therapy Insights
          • Opportunity: An Agent With Better Weight-Loss Efficacy
          • Opportunity: An Agent That Can Improve Cardiovascular Complications
          • Opportunity: An Agent With Improved Renal Benefits
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
        • Attribute Importance and Part-Worth Utilities
          • Type 2 Diabetes Target Product Profile: Attribute Importance
          • Mean Reduction in HbA1c Levels From Baseline After One Year
          • Change in Body Weight After One Year
          • Reduction in Major Adverse Cardiovascular Event (MACE) Rates Versus Placebo
          • Effect on Adverse Renal Conditions
          • Dropout % Due to Mild-Moderate Adverse Events (e.g., Gastrointestinal Issues)
          • Dosing Burden
          • Price Per Day of Therapy
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Type 2 Diabetes Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Type 2 Diabetes Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Type 2 Diabetes Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography